Faculty Bibliography

PURPOSE OF REVIEW/UNASSIGNED:Dysphagia is a common medical condition among the geriatric population that can significantly impact a patient's quality of life. The manifestations, diagnosis, and treatment of esophageal dysphagia differ greatly based on the underlying etiology, especially in older individuals who may have accompanying complex medical comorbidities. This review explores the intricacies of esophageal dysphagia in the older population and how they are managed. RECENT FINDINGS/UNASSIGNED:Novel modalities, like the functional luminal imaging probe (FLIP) and timed barium esophagram (TBE), are now woven into our diagnostic schemas for esophageal dysphagia. Studies have also looked at the safety profile of available therapeutic interventions for older individuals. There are newer, less invasive treatment options, including radiofrequency application (RFA) and transoral incisionless fundoplication (TIF) for GERD management, that may benefit the geriatric population. SUMMARY/UNASSIGNED:In this review, we discuss the most likely etiologies of esophageal dysphagia in the elderly population. We then explore a diagnostic schema and highlight treatment choices based on diagnosis. Our review specifically explores the risks and benefits of management options in more medically complex geriatric patients.

INTRODUCTION/UNASSIGNED:In the general population, right I-sided dysplasia presents a higher risk for colorectal cancer (CRC) and metachronous dysplasia compared to left (L)-sided dysplasia. Given that patients with inflammatory bowel disease (IBD) are at higher risk for dysplasia than the general population, we sought to assess the risk factors as well as the differences in outcomes between patients with R-sided, L-sided, and both R- and L-sided dysplasia. METHODS/UNASSIGNED:A retrospective chart review was performed on patients at NYU Langone Health who had evidence of dysplasia on a colonoscopy between 2011 and 2021. Demographics and pertinent medical history were compiled. Cohorts were based on the dysplasia location (R-sided, L-sided, or R- and L-sided) and the IBD-related outcomes were analyzed. RESULTS/UNASSIGNED:= 0.03). CONCLUSIONS/UNASSIGNED:Patients with UC had a higher risk for L-sided colonic dysplasia compared to patients with CD; however, there were no differences in the progression of dysplasia between those who had R-sided and those who had L-sided dysplasia. Larger studies are needed to assess the risk factors and outcomes related to the laterality of dysplasia and further validate these findings among patients with IBD.

New York City has been the epicenter of multiple recent infectious disease outbreaks, including COVID-19 and mpox, due to its position as one of the largest international travel hubs in the United States. In response to the imperative need to transport patients to specialized biocontainment units during high-consequence infectious disease outbreaks, the Health and Human Services Region 2 Regional Emerging Special Pathogen Treatment Center at New York City Health + Hospitals/Bellevue and the NYC Department of Health and Mental Hygiene spearheaded a comprehensive patient transport system. Informed by real-world experiences, quarterly drills, and regional partner engagement, the updated Region 2 patient transport concept of operations (CONOPS) ensures safe and seamless patient transfers. This article elucidates key components of the patient transport CONOPS, the multifaceted partner engagement approach used to develop it, and the collaborative workshop that fine-tuned the plan. Organizational skills, partner engagement, and adaptability were all necessary for refining and operationalizing a robust patient transport CONOPS. The finalization of this plan speaks to the collaborative spirit and commitment of regional leaders to ensure the effective management of high-consequence infectious disease outbreaks and the safeguarding of public health within Region 2 and beyond.

CONTEXT/BACKGROUND:The biochemical diagnosis of carcinoid syndrome (CS) is established through the measurement of 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA), but these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might constitute a more reliable and convenient alternative to diagnose CS. OBJECTIVE:To assess the diagnostic value of serum 5-HIAA measurements in patients with CS. DESIGN/METHODS:Retrospective cohort study. SETTING/METHODS:Tertiary care hospital. PATIENTS/METHODS:379 patients with a neuroendocrine tumor (NET), of whom 136 (35.9%) had CS, and 153 control samples were included. INTERVENTION/METHODS:Paired serum and 24-hour urine 5-HIAA measurements. MAIN OUTCOME MEASURE(S)/METHODS:Performances of serum and 24-hour urine 5-HIAA for the diagnosis of CS, measured by area under the receiver operating characteristics curve (AUROC). RESULTS:Serum 5-HIAA performance was similar to that of 24-hour urine 5-HIAA for the diagnosis of CS in the total NET cohort (n=379, AUROC 0.824 vs. 0.843, p=0.50) and in a subgroup of somatostatin analogue (SSA)-naïve patients (n=141, AUROC 0.915 vs. 0.938, p=0.66). Optimal cutoff value of serum 5-HIAA for the diagnosis of CS was 139.4 nmol/L (sensitivity 96.3%, specificity 87.6%) as determined in a subgroup analysis of SSA-naive patients with CS and controls. Serum 5-HIAA correlated well with 24-hour urine 5-HIAA (r=0.892, p<0.001) and the presence of flushing, diarrhea and carcinoid heart disease (OR 1.047-1.073 for every 100 nmol/L increase, p<0.001). CONCLUSIONS:Serum 5-HIAA measurements are equivalent to 24-hour urine 5-HIAA measurements for the diagnosis of CS in patients with NET and form an accessible alternative.

Guideline-directed medical therapy is the backbone of heart failure treatment. However, patients continue to experience heart failure symptoms, impaired quality of life, and reduced functional status despite guideline-directed medical and device treatment. There is a void in treatment alternatives between guideline-directed therapy and the advanced heart failure surgical options of heart transplant (HT) and left ventricular assist device (LVAD). Cardiac contractility modulation and baroreceptor activation therapies are shown to improve heart failure symptoms, quality of life, and exertional capacity in select patients and complement our current treatment paradigm. The purpose of this paper is to review these novel Food and Drug Administration (FDA)-approved heart failure therapies and facilitate the identification of appropriate candidates.

BACKGROUND:Abdominal computed tomography (CT) is commonly performed in adults. Abdominal aortic calcification (AAC) can be visualized and quantified using artificial intelligence (AI) on CTs performed for other clinical purposes (opportunistic CT). We sought to investigate the value of AI-enabled AAC quantification as a predictor of coronary artery disease and its association with cardiovascular events. METHODS:A fully automated AI algorithm to quantify AAC from the diaphragm to aortic bifurcation using the Agatston score was retrospectively applied to a cohort of patient that underwent both non-contrast abdominal CT for routine clinical care and cardiac CT for coronary artery calcification (CAC) assessment. Subjects were followed for a median of 36 months for major adverse cardiovascular events (MACE, composite of death, myocardial infarction [MI], ischemic stroke, coronary revascularization) and major coronary events (MCE, MI or coronary revascularization). RESULTS:Our cohort included 3599 patients (median age 60 years, 62% male, 74% white) with an evaluable abdominal and cardiac CT. There was a positive correlation between presence and severity of AAC and CAC (r=0.56, P<0.001). AAC showed excellent discriminatory power for detecting or ruling out any CAC (AUC for PREVENT risk score 0.701 [0.683 to 0.718]; AUC for PREVENT plus AAC 0.782 [0.767 to 0.797]; P<0.001). There were 324 MACE, of which 246 were MCE. Following adjustment for the 10-year cardiovascular disease PREVENT score, the presence of AAC was associated with a significant risk of MACE (adjHR 2.26, 95% CI 1.67-3.07, P<0.001) and MCE (adjHR 2.58, 95% CI 1.80-3.71, P<0.001). A doubling of the AAC score resulted in an 11% increase in the risk of MACE and a 13% increase in the risk of MCE. CONCLUSIONS:Using opportunistic abdominal CTs, assessment of AAC using a fully automated AI algorithm, predicted CAC and was independently associated with cardiovascular events. These data support the use of opportunistic imaging for cardiovascular risk assessment. Future studies should investigate whether opportunistic imaging can help guide appropriate cardiovascular prevention strategies.

Objectives Improve concordance between patient end-of-life preferences and code status orders by incorporating data from a state registry with Clinical Decision Support (CDS) within the electronic health record (EHR) to preserve patient autonomy and ensure that patients receive care that aligns with their wishes. Methods Leveraging a Health Information exchange (HIE) interface between the New York State Medical Orders for Life-Sustaining Treatment (eMOLST) registry and the EHR of our academic health system, we developed a bundled CDS intervention that displays eMOLST information at the time of code status ordering and provides an in-line alert when providers enter a resuscitation order discordant with wishes documented in the eMOLST registry. To evaluate this intervention, we performed a segmented regression analysis of an interrupted times series to compare percentage of discordant orders before and after implementation among all hospitalizations for which an eMOLST was available. Results We identified a total of 3648 visits that had an eMOLST filed prior to inpatient admission and a code status order placed during admission. There was a statistically significant decrease of discordant resuscitation orders of -5.95% after the intervention went live, with a relative risk reduction of 25%, [95% CI: -9.95%, -1.94%, p=0.009] in the pre- and post-intervention period. Logistic regression model after adjusting for co-variates showed an average marginal effect of -5.12% after the intervention [CI =-9.75%, -0.50%, p=0.03]. Conclusions Our intervention resulted in a decrease in discordant resuscitation orders. This study demonstrates that accessibility to eMOLST data within the provider workflow supported by CDS can reduce discrepancies between patient end-of-life wishes and hospital code status orders.

BACKGROUND:Objective measures and large datasets are needed to determine aspects of the Clinical Learning Environment (CLE) impacting the essential skill of clinical reasoning documentation. Artificial Intelligence (AI) offers a solution. Here, the authors sought to determine what aspects of the CLE might be impacting resident clinical reasoning documentation quality assessed by AI. METHODS:In this observational, retrospective cross-sectional analysis of hospital admission notes from the Electronic Health Record (EHR), all categorical internal medicine (IM) residents who wrote at least one admission note during the study period July 1, 2018- June 30, 2023 at two sites of NYU Grossman School of Medicine's IM residency program were included. Clinical reasoning documentation quality of admission notes was determined to be low or high-quality using a supervised machine learning model. From note-level data, the shift (day or night) and note index within shift (if a note was first, second, etc. within shift) were calculated. These aspects of the CLE were included as potential markers of workload, which have been shown to have a strong relationship with resident performance. Patient data was also captured, including age, sex, Charlson Comorbidity Index, and primary diagnosis. The relationship between these variables and clinical reasoning documentation quality was analyzed using generalized estimating equations accounting for resident-level clustering. RESULTS:Across 37,750 notes authored by 474 residents, patients who were older, had more pre-existing comorbidities, and presented with certain primary diagnoses (e.g., infectious and pulmonary conditions) were associated with higher clinical reasoning documentation quality. When controlling for these and other patient factors, variables associated with clinical reasoning documentation quality included academic year (adjusted odds ratio, aOR, for high-quality: 1.10; 95% CI 1.06-1.15; P <.001), night shift (aOR 1.21; 95% CI 1.13-1.30; P <.001), and note index (aOR 0.93; 95% CI 0.90-0.95; P <.001). CONCLUSIONS:AI can be used to assess complex skills such as clinical reasoning in authentic clinical notes that can help elucidate the potential impact of the CLE on resident clinical reasoning documentation quality. Future work should explore residency program and systems interventions to optimize the CLE.

Non-mutational epigenetic reprogramming is considered an important enabling characteristic of neoplasia. Corticotroph tumors and other subtypes of pituitary tumors are characterized by distinct epigenetic profiles. The DNA methylation profile is consistent with disease-specific gene expression, which highlights the importance of epigenetic changes in tumor formation and progression. Elucidating the epigenetic changes underlying tumorigenesis plays an important role in understanding the molecular pathogenesis of corticotroph tumors and may ultimately contribute to improving tumor-specific treatment. Here, we provide an overview of the epigenetic landscape of corticotroph tumors. We also review the role of epigenetics in silencing the expression of tumor suppressor genes and promoting oncogenes expression, which could potentially be involved in the pathogenesis of corticotroph tumors. We briefly discuss microRNAs and epigenetic aspects of POMC regulation. Lastly, since the epigenetic changes are reversible, we discuss drugs that target epigenetic modifiers that could potentially be used in the arsenal of Cushing's disease treatment modalities.